|
1) Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimerʼs disease: the Alzheimerʼs Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005; 1: 55-66
|
|
|
|
2) Aisen PS, Petersen RC, Donohue MC, et al. Clinical Core of the Alzheimerʼs Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010; 6: 239-46
|
|
|
|
|
|
3) Jack CR Jr, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimerʼs disease neuroimaging initiative. Alzheimers Dement. 2010; 6: 212-20
|
|
|
|
|
|
4) Jagust WJ, Bandy D, Chen K, et al. The Alzheimerʼs Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010; 6: 221-9
|
|
|
|
|
|
5) Trojanowski JQ, Vandeerstichele H, Korecka M, et al. Update on the biomarker core of the Alzheimerʼs Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010; 6: 230-8
|
|
|
|
|
|
6) Beckett LA, Harvey DJ, Gamst A, et al. The Alzheimerʼs Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010; 6: 257-64
|
|
|
|
|
|
7) Petersen RC, Aisen PS, Beckett LA, et al. Alzheimerʼs Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74: 201-9
|
|
|
|
|
|
8) Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimerʼs Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging, 2008; 27: 685-9
|
|
|
|
|
|
9) Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009; 73: 1193-9
|
|
|
|
|
|
10) Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Alzheimerʼs Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimerʼs disease neuroimaging initiative subjects. Ann Neurol. 2009; 65: 403-13
|
|
|
|
|
|
11) Iwatsubo T. Japanese ADNI: present status and future. Alzheimers Dement. 2010; 6: 297-9
|
|
|
|
|
|
12) Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009; 65: 557-68
|
|
|
|
|
|
13) Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009; 73: 754-60
|
|
|
|
|
|
14) Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimerʼs disease: implications for sequence of pathological events in Alzheimerʼs disease. Brain. 2009; 132: 1355-65
|
|
|
|
|
|
15) Cummings JL. Integrating ADNI results into Alzheimerʼs disease drug development programs. Neurobiol Aging. 2010; 31: 1481-92
|
|
|
|
|
|
16) Weiner MW, Aisen PS, Jack CR Jr, et al. The Alzheimerʼs disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010; 6: 202-11
|
|
|
|
|
|
17) Aisen P: Treating Before Symptoms-ADCS Invites Ideas for Clinical Trials in Very Early AD. Web Discussions at Alzforum. June 9, 2010. (http://www.alzforum.org/res/for/journal/detail.asp？liveID＝180)
|
|
|
|
|